chrisvoncsefalvay/vaers-outcomes huggingface dataset:
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE SLEEP APNEA ADULT OBSTRUCTIVE SLEEP APNEA PERIPHERAL NEUROPATHY ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPERCAPNIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPERCAPNIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/8/2022,  5/26/2022,  6/13/2022,  7/7/2022,  7/31/2022,  9/8/2022,  10/11/2022,  10/25/2022,  2/5/2022,   11/12/2022,  12/21/2022,  2/1/2023,  3/12/2023,  3/2/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Developed metallic taste morning after vaccine given for 3-4 days. Then reported today that a couple weeks ago  right hand  started to swell and tingle which comes and goes.
Throat became full on both sides & back of throat numb. Began 3 minutes after injection & lasted for 1 hour. Heart racing, hot flash which continued to last for 30 minutes
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 29-year-old male patient received BNT162b2 (BNT162B2), on 01Apr2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 28 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa" (unspecified if ongoing), notes: Known allergies: Sulfa. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of covid-19.  Clinical Course: It was reported that, the patient received Paxlovid from 20May2022 to 23May2022 for treatment of COVID-19. The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously received a COVID-19 Vaccine. The patient reported to had Dysgeusia (grapefruit-soap like taste during Paxlovid treatment).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the event DRUG INEFFECTIVE and COVID-19 and BNT162B2.
Right upper extremity deep venous thrombosis in the brachial, basilic, and median cubital veins.; This is a spontaneous report from a contactable other hcp.  A 34-year-old female patient (not pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number was not reported) intramuscular in Arm Right on 11Sep2021 (at 34 years)as single dose for covid-19 immunisation .  Medical history included smoker, anxiety, depression. No Known allergies. No covid prior vaccination and not covid tested post vaccination.Concomitant medications included sertraline hydrochloride (ZOLOFT) and  gabapentin, both  taken for an unspecified indication, start and stop date were not reported.  On 14Sep2021 patient experienced right upper extremity deep venous thrombosis in the brachial, basilic, and median cubital veins. Event resulted in Doctor or other healthcare professional office/clinic visit. Patient was treated with Eliquis 10 mg. The outcome of the event was recovering.The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow-up.; Sender's Comments: Based on the limited information in the case, a contributory effect of the vaccine BNT162B2 to the reported event Deep vein thrombosis cannot be ruled out. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
patients hands became red and swollen with a noticeable increased edema in the left hand with in the first 5 minutes of receiving vaccine.  Both hands showed demarcation of red coloring at wrist. Left hand was warm to touch and "felt off" according to patient. during the course of 10 minutes swelling and color difference diminished slightly but was still present 30 minutes post vaccine administration.
he's imagining people are here and he is talking to them/wakes up screaming talking to people who aren't present; Tries to leave the house/ wakes up sometimes and acts as if he is eating and does all of the motions as if he is using a spoon and chewing but he hasn't ate anything; He doesn't recognize where he is; This is a spontaneous report from a contactable consumer. An 87-year-old male patient (also the age at vaccination)  received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot: EM9809), first dose via an unspecified route of administration, administered in Arm Right on 04Feb2021 02:45 PM as SINGLE DOSE for covid-19 immunization. Medical history included remission from cancer, he has Hypertension (reported also as High Blood Pressure/Hypertension), thyroid disorder (reported as Thyroid), blood cholesterol abnormal (reported as Cholesterol), light symptoms about once or twice a month of disorientation, vision impaired, a PaceMaker and soft stool (reported as Stool: stool softener).  The patient is not aware of any allergies to medications, food, or other products. The patient was vaccinated the most recent COVID-19 vaccine in a hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19 and not been tested for COVID-19 since the vaccination. The patient had other medications the patient received within 2 weeks of vaccination for High Blood Pressure, Thyroid, Cholesterol, and Stool Softener. It was reported that the patient has had light symptoms about once or twice a month of disorientation. However since he's received the vaccine he has not had any fever with either dose but has throughout the day and night doesn't know where he is, he's imagining people are here and he is talking to them. He doesn't recognize where he is at, at times. He wakes up screaming talking to people who aren't present. Tries to leave the house even though he is vision impaired and has never tried to leave the house on his own. He wakes up sometimes and acts as if he is eating and and does all of the motions as if he is using a spoon and chewing but he hasn't ate anything and there isn't any food near him because he is in his bed. It was reported that the events occurred on 06Feb2021. The events were not considered as serious by the reporter (for any criteria). The outcome of the events was not recovered. No treatment was received for the adverse events.
Lymph node inflammation in the collarbone area; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENITIS (Lymph node inflammation in the collarbone area) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031H21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included SPIRONOLACTONE for an unknown indication.    On 04-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Dec-2021, the patient experienced LYMPHADENITIS (Lymph node inflammation in the collarbone area). At the time of the report, LYMPHADENITIS (Lymph node inflammation in the collarbone area) outcome was unknown.            No treatment medications provided by the reporter.
4 d after shot developed sudden onset of severe pain in left shoulder, left arm (same arm shot given in).
Area approximately 20 x 10mm of erythema at site of varicella vaccine (Right arm; subcutaneous area) 2 days after injection.  Slight warmth at site
The grandmother of an 18 month old female reported that her granddaughter received Tetramune on 11/13/96. Within 3 weeks of immunization, she developed seizures, vomiting and diarrhea and she was hospitalized. The reported indicated that the child now has a learning disability, gross motor problems, unsteady on her feet and falls down. and has pervasive development disorder. Follow up info received on 4/4/00 indicated that the vaccine provider had "No information in clinic chart to support this claim." The pt was last seen by the vaccine provider in the clinic on 9/18/97. The vaccine provider also indicated that no reactions or parental phone calls have been documented in the clinic chart concerning adverse events following prior vaccination in pt or sibling.
The morning after first  vaccination I noticed tightness and inflammation in the lymph  nodes  in my underarm area.  Days  later muscle inflammation  throughout my arm  progressively worst  accompanied by occasional tingling  in the fingers,  After the second week  I had a virtual  office visit with  my PPC doctor who said  this was a common side effect and so I just let it take its  course.  After my second shot  (2/15/) the same  feelings have occurred but  even more acute.  Keeping me awake at night etc.
BRUISING AT AREA OF PREVIOUS INJURY OF LEFT ELBOW AND RIGHT ANKLE; This spontaneous report received from a patient concerned a 64 year old female. The patient's height, and weight were not reported. The patient's past medical history included: banged her left elbow really bad, and hit her right ankle on a stick. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 19-MAY-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Non-company suspect drugs included: semaglutide (form of admin, route of admin, and batch number were not reported) dose, frequency, and therapy dates were not reported for an unspecified indication; and insulin degludec (form of admin, route of admin, and batch number were not reported) dose, frequency, and therapy dates were not reported for an unspecified indication. No concomitant medications were reported. On 26-MAY-2021, the patient experienced bruising at area of previous injury of left elbow and right ankle. The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and action taken with semaglutide, and insulin degludec was not reported. The patient recovered from bruising at area of previous injury of left elbow and right ankle. This report was non-serious.
NUMB LEFT CHEEK; This spontaneous report received from a patient concerned a 49 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, and batch number: UNKNOWN expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. No concomitant medications were reported. On 14-APR-2021, the subject experienced numb left cheek. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from numb left cheek. This report was non-serious.
Patient projectile vomited large amounts immediately upon dosing with 2-3 drops of ROTATEQ. MA attempted x2, both times pt had projectile vomiting. Mom denies any history of spitting or vomiting.
53 y/o female with no known medical history, who presents with nausea post vaccination administration. Patient states that this is her 2nd vaccination in the two-dose series. Patient denies previous reaction to vaccinations in the past. Patient denies sore throat, difficulty breathing, chest pain or itch. NP and Paramedics at patient side. Patient vitals all within normal limits (128/88 BP, 100% RA, 61 HR, Resp 14). Patient provided a mint (as requested) and placed in Trendelenburg. Patient monitored for 10 mins with resolution of symptoms. Patient stated that she felt better and that she was ok to go home. Patient was cleared to be discharged home by the NP.
Patient called and reported that at 430 pm of 08/19/2019 she developed a rash under her Left arm, across abdomen and on left leg. No complaints of itching
Patient received Moderna vaccine at age 17 years (less than EUA age range of 18 years+) Patient received dose 1 on March 2, 2021 and dose 2 on March 30, 2021
patient called 9/15/22 reported of arm swelling, redness, itching and generally swollen. patietn was advised to monitor and take a benadyrl as well as ice and use pain control otc if needed. Possible result due to difficult to get to the shoulder, pt was unable to get shirt up enough to expose the shoulder, in order to get the shot it was required to pull the sleeve up and created a pressure on the arm which may have lead to the event
This spontaneous report has been received from a Registered Nurse referring to a patient of unknown age and gender. No concurrent or historical condition was reported. On 28-JUL-2015 the patient was vaccinated with improperly stored dose of GARDASIL, lot # K023432, expiration date: 18-JUN-2016, dose, route, frequency and anatomical location were unknown. No adverse symptoms reported. No product quality complaint was reported. This is one of several cases received from the same source (MARRS number: 1508USA003819, 1508USA005117, 1508USA005118, 1508USA005119, 1508USA005120, 1508USA005121, 1508USA005122, 1508USA005123, 1508USA005125). Additional information has been requested.
Patient is 17 years old and was incorrectly screened and was given the Moderna vaccine.
Two weeks after this injection develop severe joint pain in my shoulder, hips and knees; Symptoms of aching in my body; Fever; Chills; Severe swelling at the injection site for 2 weeks; This spontaneous case was reported by a nurse and describes the occurrence of MYALGIA (Symptoms of aching in my body), PYREXIA (Fever), CHILLS (Chills), INJECTION SITE SWELLING (Severe swelling at the injection site for 2 weeks) and ARTHRALGIA (Two weeks after this injection develop severe joint pain in my shoulder, hips and knees) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2021, the patient experienced ARTHRALGIA (Two weeks after this injection develop severe joint pain in my shoulder, hips and knees). On an unknown date, the patient experienced MYALGIA (Symptoms of aching in my body), PYREXIA (Fever), CHILLS (Chills) and INJECTION SITE SWELLING (Severe swelling at the injection site for 2 weeks). At the time of the report, MYALGIA (Symptoms of aching in my body), PYREXIA (Fever), CHILLS (Chills) and INJECTION SITE SWELLING (Severe swelling at the injection site for 2 weeks) had resolved and ARTHRALGIA (Two weeks after this injection develop severe joint pain in my shoulder, hips and knees) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information provided. Exactly two weeks after receiving the injection,patient developed severe joint pain in shoulder, hips and knees. No treatment medication information provided.   This case was linked to MOD-2022-511125 (Patient Link).
chills; felt like someone punched me in the back; low grade fever; pain when I would breath; This is a spontaneous report from a contactable consumer (patient). A female patient of unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route on 17Feb2021 (12 days past the 21 days) as a single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection) as a single dose for covid-19 immunization and her arm was sore. On an unknown date, patient experienced chills, felt like someone punched her in the back, had low grade fever, and had pain when she would breathe. She had no antibodies when they checked. She got an antibody test they pricked her finger and said she had no antibodies (negative IgC and IgM). They advised her to come back in 1 month to test again. The patient underwent lab test and procedure, which included antibody test they pricked her finger and said she had no antibodies (negative IgC and IgM). The clinical outcome of the events was unknown.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Chills; Fever 100.1degrees F; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 10:00 (at the age of 71 years) as a single dose for COVID-19 immunisation. Medical history included multiple strokes, multiple sclerosis, breast and lung cancer and allergy (unspecified) on unknown dates. The patient received other medications within 2 weeks of vaccination (not reported as it was too many to get it listed). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration, on 24Feb2021 at 10:00 in the left arm as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 12:15, the patient experienced chills commencing 62 hours after second dose followed by fever. Therapeutic measures taken as a result of reported events included 2 Tylenol of 500 mg capsules. The clinical outcome of chills and fever were recovered on an unknown date in 2021.   Information about lot/batch number cannot be obtained. No further information is expected.
Patient was admitted for acute toxic metabolic encephalopathy and acute confusion. He was found to be COVID-19 positive, but appears asymptomatic.
after completing first booster her labs were elevated; fatty liver disease / labs were elevated; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for COVID-19 immunization. The patient's relevant medical history included: "diagnosis of fatty liver disease" (unspecified if ongoing), notes: Patient has a diagnosis of fatty liver disease due to a medication. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (completed primary series, DOSE 2), for COVID-19 immunization; Bnt162b2 (completed primary series, DOSE 1), for COVID-19 immunization. The following information was reported: CONDITION AGGRAVATED (non-serious), outcome "unknown", described as "after completing first booster her labs were elevated"; LIVER FUNCTION TEST INCREASED (non-serious), outcome "unknown", described as "fatty liver disease / labs were elevated". The patient underwent the following laboratory tests and procedures: Liver function test: Result unknown, notes: completes labs for monitoring; no change, notes: After primary series; elevated, notes: After first booster.  Additional information: Patient had a diagnosis of fatty liver disease due to a medication. She completed labs for monitoring. She completed primary series and no change in labs but after completing first booster her labs were elevated. Event took place after use of product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Had two flu shots, was sicker than patient have ever been in my life; Initial information received on 24-Oct-2020 regarding an unsolicited valid serious case received from a consumer (patient) via social media.  This case is linked to case 2020SA308167, 2020SA308168, 2020SA308169, 2020SA308170, 2020SA308163, 2020SA308172, 2020SA308173, 2020SA308174, 2020SA308175 and 2020SA308171 (same reporter).  This case involves a patient of unknown age who had two flu shots, was sicker than patient had ever been in his/her life (illness), while patient was treated with Influenza Vaccine.  Medical history included pneumonia after pneumonia vaccination.   Medical treatment(s) and family history were not provided.  Concomitant medication was not reported.  On an unknown date, the patient received influenza vaccine of unknown manufacturer [lot number: unknown and expiration date: unknown] at an unknown dose via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, (latency: unknown) after starting the suspect vaccine therapy, was sicker than patient had ever been in his/her life (illness).  No laboratory data was reported.  No corrective treatment (preventive medicine) was received.  At the time of reporting, outcome of the events were unknown.  There will be no information available regarding batch number in this case.
body ache; Fever; chills; fatigue; This is a spontaneous report from a contactable consumer. A 49-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 25Mar2021 at 10:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included amlodipine besilate (NORVASC) and cetirizine hydrochloride (ZYRTEC) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 10:00, the patient experienced fever, chills, fatigue and body ache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events fever, chills, fatigue and body ache. The clinical outcomes of the events fever, chills, fatigue and body ache were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
A serious clinical trial report of Grade 3 depression was received from an Investigator concerning a 17 year-old female, subject number (2018007) who is enrolled in a study. The subject's past medical history and concomitant medications were not reported. The subject received one dose of MEDI3414 or placebo on 17-Aug-2009 intranasally. On 13-Sep-2009 the subject was hospitalized for depression. The event of depression was reported as ongoing. The Study Investigator reported the causality of the depression to MEDI3414 or placebo as none.
Developed  severe vestibular neuritis with veritgo and nausea that has lasted several days and is still continuing with severe vertigo